{
    "nct_id": "NCT04143516",
    "official_title": "Clinical Trial Optimizing Tumor Ablation for Liver Metastases: Rapid Tissue Analysis Allowing for Immediate Retreatment; Metabolic Imaging Biomarker Validation; and Predictive Genetic Signatures",
    "inclusion_criteria": "* Diagnosis of liver metastases from various primary tumors\n* Confined liver disease or limited extrahepatic disease stable/controlled for at least 4 months (extrahepatic disease amenable to treatment is allowed)\n* Lesions of ≤3 cm in maximum diameter\n* At least one FDG-avid lesion to be treated***\n* INR < 1.5*\n* Platelet count ≥ 50,000\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Age < 18\n* Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from ablation injury with technical modifications such as hydro or air dissection\n* INR > 1.5 that cannot be corrected with fresh frozen plasma **\n* Platelet count of <50,000 that cannot be corrected with transfusion\n* More than 3 tumors in the liver\n* More than 5 tumors of extrahepatic disease (including mediastinal nodes and pulmonary nodules, abdominal or other lymph nodes, and bone metastasis)\n* Presence of any peritoneal Carcinomatosis\n\n  * For patients on Coumadin, general clinical guidelines for IR ablation will be followed.\n\n    * For patients with no FDG-PET avid tumors aim 2 of the protocol will not be assessed",
    "miscellaneous_criteria": ""
}